d4a5a598c2410dddc7dbc546b392f291

Michael S. Ip, MD

Clinical Specialties
\

Diabetic retinopathy

\

Age-related macular degeneration

\

Retinal Vein occlusion

\

Vitreoretinal surgery

Academic Degrees
\

Bachelor of Science

Tufts University
\

Doctor of Medicine

New York University School of Medicine
Residency
\

Ophthalmology

University of Pittsburgh School of Medicine
Fellowships
\

Vitreoretinal Surgery

New England Eye Center
Tufts University
Research Interests
My research interest focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, age-related macular degeneration, retinal venous occlusive disease and other retinal diseases. Previously, as the Co-Director of the Fundus Photograph Reading Center, I assisted with the collection, analysis, and dissemination of important primary and secondary outcomes in ophthalmic clinical trials. Early in my career, I had focused primarily on industry sponsored trials such as the Eli Lilly trials for protein kinase C inhibitor for diabetic macular edema (MBBK), transpupillary thermotherapy of occult subfoveal choroidal neovascular membranes in patients with age-related macular degeneration (TTT4CNV trial), the Control Delivery Systems trials evaluating intravitreal fluocinolone implants, and the Bausch and Lomb trials investigating fluocinolone acetonide intravitreal implants. I served both as a clinical site investigator and on advisory boards and writing committees. In 2003, I was selected to serve as the national protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema (protocol B).

This was a landmark study and changed practice patterns in the field of ophthalmology. In 2003, my independent and investigator-initiated research group received a U-10 cooperative agreement award from the National Eye Institute, National Institutes of Health to conduct the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. This was a multicenter, randomized, NIH-defined phase 3 trial which led to over 15 publications in the peer-reviewed literature and provided much needed Level 1 evidence to guide our management of retinal venous occlusive disease. In 2013, this group received funding from the NEI to conduct the SCORE2 Study. The SCORE2 Study is an NIH-defined phase 3 clinical trial designed to evaluate the comparative efficacy and safety of bevacizumab versus aflibercept for the treatment of macular edema secondary to central retinal vein occlusion. Over 360 participants were enrolled and the 6 month and 12 month data are in the manuscript preparation stage. This study group has an application in place to extend the SCORE2 follow up phase out to 5 years to evaluate long-term safety and efficacy outcomes in central retinal vein occlusion.

Selected Publications

Scott IU, Blodi BA, Ip MS, VanVeldhuisen PC, Oden NL, Chan CK, Gonzales V; SCORE Study Investigator SCORE Study Report No. 2: Interobserver Agreement Between Investigator and Reading Center Classification of Retinal Vein Occlusion Type. Ophthalmology. 2009;116(4):756-761.

Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 3. Study Design and Baseline Characteristics. 2009; Sep 116(9):1770-1777. Epub Jul 19, 2009.33.

Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH. SCORE Study Report 5: A Randomized Trial Comparing the Efficacy and Safety  of Intravitreal Triamcinolone with Observation to Treat Vision Loss Associated with Macular Edema Secondary to Central Retinal Vein Occlusion.  Arch Ophthalmol.   2009;127(9):1101-1114.

Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M.  SCORE Study Report 6: A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone with Standard Care to Treat Vision Loss Associated with Macular Edema Secondary to Branch Retinal Vein Occlusion.  Arch Ophthalmol. 2009;127(9):1115-1128

Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression.  Arch Ophthalmol.  2012 Sep;130(9):1145-52.

Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-Term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening of Retinopathy.  Ophthalmology, 2014 Nov;18(14):822-7.

Domalpally A, Ip MS, Ehrlich JS. Effects of Intravitreal Hard Exudate in Diabetic Macular Edema: Findings from the RIDE and RISE Phase 3 Clinical Trials.  Ophthalmology, 2015 Feb:1-8.

Selected Awards & Honors

1993  Alpha Omega Alpha, New York University School of Medicine, New York, NY.
1994  Finalist for Wholeness of Life Award, Lenox Hill Hospital, New York, NY.
1996  First Place Award, Outstanding Resident Presentation, University of Pittsburgh School of Medicine, Pittsburgh, PA, 1996 Resident’s Day.
1997  Jay G. Linn Award, Most Outstanding Resident, University of Pittsburgh School of Medicine, Pittsburgh, PA.
1999  Oliver Smith Award, New England Eye Center, Tufts University, Boston, MA.
2000  Outstanding Surgical Instructor to Resident Education, University of Wisconsin, Department of Ophthalmology and Visual Sciences.
2002  Teacher of the Year Award (Resident Education), University of Wisconsin, Department of Ophthalmology and Visual Science.
2005  Achievement Award, American Academy of Ophthalmology, San Francisco, CA.
2006  Teacher of the Year Award (Resident Education), University of Wisconsin, Department of Ophthalmology and Visual Sciences.
2009  Leadership Development Program Award, LDP XII (Class of 2010), American Academy of Ophthalmology. San Francisco, CA.
2012  Senior Achievement Award, American Academy of Ophthalmology. Chicago, IL
2014  Physician Leadership Development Program. University of Wisconsin Medical Foundation
2015  Macula Society, Young Investigator Award. Given “To that individual or group of individuals under 50 years of age whose work gives promise of notable advance in the clinical treatment of disorders of the eye.” Scottsdale, AZ.
2016  Teacher of the Year Award (Resident Education), University of Wisconsin, Department of Ophthalmology and Visual Science.
2019  Senior Achievement Award, American Academy of Ophthalmology

Board Certifications
\

American Board of Ophthalmology

Office Locations
\

Doheny Eye Center UCLA
Arcadia

622 W. Duarte Road
Suite 101
Arcadia, CA 91007
626.254.9010
\

Doheny Eye Center UCLA
Pasadena

625 South Fair Oaks Ave.
Suite 280
Pasadena, CA 91105
626.817.4747